Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prothena Corporation plc (PRTA : NSDQ)

• Company Description    Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements. Number of Employees: 67

• Price / Volume Information    Yesterday's Closing Price: $9.83 Daily Weekly Monthly 20 Day Moving Average: 507,699 shares Shares Outstanding: 52.35 (millions) Market Capitalization: $514.63 (millions) Beta: -0.23 52 Week High: $11.80 52 Week Low: $4.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.39% -12.86% 12 Week 13.77% 5.18% Year To Date 2.93% -9.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS - DUBLIN 2,L2 D02 VK60 IRL ph: 011-353-1236-2500 fax: 353-1902-3510 mark.johnson@prothena.com http://www.prothena.com

• General Corporate Information    Officers Gene G. Kinney - Chief Executive Officer and President Daniel G. Welch - Chair of the Board Tran B. Nguyen - Chief Financial Officer Richard T. Collier - Director Shane M. Cooke - Director Peer Information Prothena Corporation plc (CORR.) Prothena Corporation plc (RSPI) Prothena Corporation plc (CGXP) Prothena Corporation plc (BGEN) Prothena Corporation plc (GTBP) Prothena Corporation plc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G72800108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 52.35 Most Recent Split Date: (:1) Beta: -0.23 Market Capitalization: $514.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 34.72% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: 54.61 Trailing 12 Months: - PEG Ratio: 1.57 Price Ratios Price/Book: 1.65 Price/Cash Flow: - Price / Sales: 8.88 EPS Growth vs. Year Ago Period: 146.43% vs. Previous Quarter: 218.18% Sales Growth vs. Year Ago Period: 1,706.36% vs. Previous Quarter: 243,157.14% ROE 03/31/26 - -43.44 12/31/25 - -65.89 09/30/25 - -65.89 ROA 03/31/26 - -36.87 12/31/25 - -56.00 09/30/25 - -56.70 Current Ratio 03/31/26 - 10.43 12/31/25 - 7.72 09/30/25 - 6.61 Quick Ratio 03/31/26 - 10.43 12/31/25 - 7.72 09/30/25 - 6.61 Operating Margin 03/31/26 - -227.23 12/31/25 - -2,275.19 09/30/25 - -2,157.81 Net Margin 03/31/26 - -260.92 12/31/25 - -2,520.57 09/30/25 - -2,379.59 Pre-Tax Margin 03/31/26 - -184.21 12/31/25 - -2,073.82 09/30/25 - -2,025.72 Book Value 03/31/26 - 5.97 12/31/25 - 5.21 09/30/25 - 5.48 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©